Premier Fund Managers’s Teva Pharmaceuticals TEVA Stock Holding History

Premier Fund Managers’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-52,338	Closed	-$2.42M	–	54
2016 Q3	$2.42M	Sell	52,338 -1,162	-2%	-$60.6K	1.97%	27
2016 Q2	$2.69M	Buy	53,500 +8,500	+19%	+$453K	2.62%	21
2016 Q1	$2.45M	Hold	45,000	–	–	2.39%	21
2015 Q4	$2.97M	Buy	+45,000	New	+$2.78M	2.79%	3

Other funds holding TEVA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

HCM

Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return

Premier Fund Managers's TEVA Position: Q4 2016 in Review

Premier Fund Managers sold out of Teva Pharmaceuticals (TEVA) in Q4 2016, closing a stake of 52,338 shares — an estimated $2.42M sold.

Premier Fund Managers first reported a position in TEVA in Q4 2015 and held it in 4 quarters. The position peaked at $2.97M in Q4 2015. 738 funds tracked by Wall St. Rank hold TEVA as of Q4 2016.

Premier Fund Managers reported no remaining Teva Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
Premier Fund Managers sold 52,338 Teva Pharmaceuticals shares in Q4 2016, an estimated $2.42M.
Premier Fund Managers first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 4 quarters.
Premier Fund Managers's Teva Pharmaceuticals position peaked at $2.97M in Q4 2015.
738 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2016.

Based on Premier Fund Managers's 13F filing for Q4 2016, filed 10 Feb 2017.